Pulmonx (LUNG) Q1 2026 Earnings Transcript

Pulmonx reported Q1 revenue of $20.6 million, down 9% year over year, with U.S. revenue down 7% and international revenue down 12% due entirely to absent China distributor sales. Gross margin improved to 78% from 73%, operating expenses fell 6%, and the company reaffirmed 2026 guidance for $90 million to $92 million in revenue and $113 million to $115 million in operating expenses. Management said it expects year-over-year growth to improve each quarter, return to growth in the back half of 2026, and close a new $60 million credit facility that extends debt maturity to 2031.

Analysis

The setup is less about a single-quarter miss and more about whether management can convert organizational triage into durable unit growth before the balance sheet becomes the dominant narrative. The new sales force is a double-edged sword: if the 6-9 month rep ramp is real, the inflection belongs in late 2026, but that also means the first-half numbers are structurally low-quality and vulnerable to disappointment if procedures per rep do not improve fast enough. The market should treat the current period as a proof-of-execution window, not a fundamental re-rating event.

The cleanest bullish second-order effect is that the China gap artificially depresses reported international growth just as non-China ex-U.S. channels are showing healthy underlying demand. That creates an easier comp in the back half, but it also means headline acceleration may be more optical than economic if China returns only gradually. The real tell will be whether domestic account productivity, not just account additions, starts to lift gross procedure volumes; otherwise, adding centers simply increases the denominator of a slow-moving installed base.

The most underappreciated risk is capital structure flexibility masquerading as safety. A 5-year interest-only facility reduces near-term solvency risk, but it can also delay hard strategic choices if growth stalls; the stock may trade as a long-duration turnaround with clinical optionality, while the underlying business still burns cash. AeriSeal is the key longer-dated catalyst, but it is too far out to support near-term valuation unless the company can show that today’s commercial reset is already translating into slope change in 2H26. Consensus may be underestimating how much of the back-half guidance depends on a clean China administrative renewal and a smooth rep ramp occurring simultaneously.

Key Decisions for Investors

• Avoid chasing the equity on the headline guide; wait for Q2/Q3 proof that U.S. revenue inflects sequentially and that new reps are converting added centers into procedures. Better entry is after the next two prints if growth rate deceleration stops worsening.
• If long LUNG, size it as a turnaround optionality position only and pair it against a basket of stronger-capitalized medtech names to isolate execution risk; the trade works only if commercial momentum improves faster than cash burn.
• Consider a tactical short-dated call spread on LUNG into the next earnings cycle if the stock rerates on guidance alone; upside is capped by the fact that China is likely to resume gradually, not in a step function.
• For event-driven traders, use a risk-defined long only after confirmation that back-half U.S. growth is trending positive and that the China renewal is announced; the catalyst window is 2H26, not immediately.